Across TCGA pan-cancer cohorts, C2orf15 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated C2orf15 data layer compared with 26 for mass-spec protein.
The strongest signal is observed in colon adenocarcinoma (COAD), where higher C2orf15 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated C2orf15 expression acts as an unfavorable survival marker.
COAD and SKCM are the cancer types where C2orf15 Mutation most reproducibly stratifies survival.